727 related articles for article (PubMed ID: 28662313)
21. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
22. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
23. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
24. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
27. Assessment of radiotherapy combined with adjuvant chemotherapy in the treatment of patients with advanced nasopharyngeal carcinoma: a prospective study.
Kong F; Cai B; Lin S; Zhang J; Wang Y; Fu Q
J BUON; 2015; 20(1):206-11. PubMed ID: 25778317
[TBL] [Abstract][Full Text] [Related]
28. Survival without adjuvant chemotherapy for selected patients with stage II and III nasopharyngeal carcinoma after concurrent chemoradiotherapy alone.
Wu JS; Tsai YC; Jian JJ; Chen HH; Horng CF; Cheng SH
Head Neck; 2018 Sep; 40(9):2070-2077. PubMed ID: 29756398
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.
Wee J; Tan EH; Tai BC; Wong HB; Leong SS; Tan T; Chua ET; Yang E; Lee KM; Fong KW; Tan HS; Lee KS; Loong S; Sethi V; Chua EJ; Machin D
J Clin Oncol; 2005 Sep; 23(27):6730-8. PubMed ID: 16170180
[TBL] [Abstract][Full Text] [Related]
30. Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
Yan P; Yin H; Guo W; Sun X; Li F; Huang S; Bian X; Wang F; Zhang F; Wang B; Zhou H; Zhou C; Yin L; Jiang X; Jiang N; Wu J; Liu J; Song D; He X
Cancer Med; 2020 Sep; 9(17):6166-6172. PubMed ID: 32657029
[TBL] [Abstract][Full Text] [Related]
31. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
[TBL] [Abstract][Full Text] [Related]
32. Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.
Chitapanarux I; Kittichest R; Tungkasamit T; Asakit T; Chomprasert K; Chakrabandhu S; Onchan W; Traisathit P
Curr Probl Cancer; 2021 Feb; 45(1):100620. PubMed ID: 32713518
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
[TBL] [Abstract][Full Text] [Related]
34. Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicity.
Xu J; He X; Cheng K; Guo W; Bian X; Jiang X; Zhang L; Huang S
Head Neck; 2014 Oct; 36(10):1474-80. PubMed ID: 23996842
[TBL] [Abstract][Full Text] [Related]
35. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
36. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
37. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
Li XY; Chen QY; Sun XS; Liu SL; Yan JJ; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Wen YF; Guo L; Mo HY; Chen MY; Sun Y; Ma J; Tang LQ; Mai HQ
Eur J Cancer; 2019 Mar; 110():24-31. PubMed ID: 30739837
[TBL] [Abstract][Full Text] [Related]
38. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
[TBL] [Abstract][Full Text] [Related]
39. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma.
Lee AW; Tung SY; Chan AT; Chappell R; Fu YT; Lu TX; Tan T; Chua DT; O'sullivan B; Xu SL; Pang ES; Sze WM; Leung TW; Kwan WH; Chan PT; Liu XF; Tan EH; Sham JS; Siu L; Lau WH
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):142-51. PubMed ID: 16904519
[TBL] [Abstract][Full Text] [Related]
40. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Kwong DL; Sham JS; Au GK; Chua DT; Kwong PW; Cheng AC; Wu PM; Law MW; Kwok CC; Yau CC; Wan KY; Chan RT; Choy DD
J Clin Oncol; 2004 Jul; 22(13):2643-53. PubMed ID: 15226332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
